Search

Home > JACC Podcast > Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies | JACC | ACC.25
Podcast: JACC Podcast
Episode:

Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies | JACC | ACC.25
Category: Health
Duration: 00:01:41
Publish Date: 2025-04-01 14:31:46
Description:

This interview with JACC: Associate Editor Neha J. Pagidipati, MD, FACC, and author Kausik Ray, MD, FACC, reviews Dr. Ray’s phase one study on solbinsiran, an siRNA therapy targeting ANGPTL3 to reduce triglycerides and cardiovascular risk. Dr. Ray explains the study's findings, including significant reductions in triglycerides, ApoB, and LDL, with a favorable safety profile. The conversation also touches on the broader landscape of ANGPTL3 inhibitors, the implications of HDL reduction, and the anticipation of phase two results to be presented at ACC 2025.
Total Play: 0

Some more Podcasts by American College of Cardiology

500+ Episodes
JACC: Clinic .. 10+     1
1K+ Episodes
JACC's Audio .. 70+     10+